We evaluated the incidence of thrombotic events, given that patients with ITP have an increased incidence of arterial and venous thrombosis, and this risk increases with certain treatments, such as splenectomy and TPO-RA, and even more with COVID-19 infection [15]. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.